Jim Simons Sana Biotechnology, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Sana Biotechnology, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 172,900 shares of SANA stock, worth $944,034. This represents 0.0% of its overall portfolio holdings.

Number of Shares

172,900

Previous 295,100 41.41%

Holding current value

$944,034

Previous $1.2 Million 43.6%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.2 - $11.27 $513,240 - $1.38 Million	-122,200 Reduced 41.41%	172,900 $1.73 Million
Q4 2023 Feb 13, 2024	BUY	$2.8 - $4.55 $280,646 - $456,051	100,231 Added 51.44%	295,100 $1.2 Million
Q3 2023 Nov 14, 2023	BUY	$3.77 - $6.23 $734,656 - $1.21 Million	194,869 New	194,869 $754,000
Q1 2023 May 12, 2023	SELL	$3.11 - $4.92 $325,306 - $514,632	-104,600 Reduced 63.13%	61,100 $200,000
Q4 2022 Feb 13, 2023	SELL	$3.19 - $6.46 $2.08 Million - $4.21 Million	-652,300 Reduced 79.74%	165,700 $655,000

Q3 2022 Nov 14, 2022	BUY	$5.58 - $9.04 $174,096 - $282,048	31,200 Added 3.97%	818,000 $4.91 Million
Q2 2022 Aug 12, 2022	SELL	$4.12 - $9.35 $222,068 - $503,965	-53,900 Reduced 6.41%	786,800 $5.06 Million
Q1 2022 May 13, 2022	BUY	$5.24 - $15.58 $4.11 Million - $12.2 Million	783,400 Added 1367.19%	840,700 $6.94 Million
Q4 2021 Feb 11, 2022	BUY	$15.18 - $23.15 $869,814 - $1.33 Million	57,300 New	57,300 $887,000
Q3 2021 Nov 12, 2021	SELL	$16.29 - $25.88 $361,638 - $574,536	-22,200 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$16.65 - $32.14 $369,629 - $713,508	22,200 New	22,200 $436,000

Others Institutions Holding SANA

# of Institutions

156

Shares Held

124M

Call Options Held

297K

Put Options Held

124K

View Full List

About Sana Biotechnology, Inc.

Ticker SANA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 190,232,000
Market Cap $1.04B
Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...

More about SANA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account